Efficacy and safety of prucalopride in adults and children with chronic constipation

Bibliography

• Higgins PD, Johanson JF. Epidemiology of constipation in north america: a systematic review. Am J Gastroenterol 2004;99(4):750-9
   PubMed Web of Science ®Google Scholar
• Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in europe and oceania: a systematic review. BMC Gastroenterol 2008;8:5
   PubMed Web of Science ®Google Scholar
• Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol 2011;25(1):3-18
   PubMed Web of Science ®Google Scholar
• Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96(11):3130-7
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil 2011;23(8):697-710
   PubMed Web of Science ®Google Scholar
• Solzi GF, Di C. Are constipated children different from constipated adults? Dig Dis 2000;15213:308-15
   Google Scholar
• Enck P. Biofeedback training in disordered defecation: a critical review. Dig Dis Sci 1993;38:1953-60
   PubMed Web of Science ®Google Scholar
• Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology 2000;119(6):1766-78
   PubMed Web of Science ®Google Scholar
• Youssef NN, Langseder AL, Verga BJ, et al. Chronic childhood constipation is associated with impaired quality of life: a case-controlled study. J Pediatr Gastroenterol Nutr 2005;41(1):56-60
   PubMed Web of Science ®Google Scholar
• Rantis PC, Vernava AM, Daniel GL, et al. Chronic constipation–is the work-up worth the cost? Dis Colon Rectum 1997;40(3):280-6
   PubMed Web of Science ®Google Scholar
• Liem O, Harman J, Benninga M, et al. Health utilization and cost impact of childhood constipation in the united states. J Pediatr 2009;154(2):258-62
   PubMed Web of Science ®Google Scholar
• Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011(25 Suppl B):11B-5B
   PubMedGoogle Scholar
• Wald A, Mueller-Lissner S, Kamm MA, et al. Survey of laxative use by adults with self-defined constipation in south america and asia: a comparison of six countries. Aliment Pharmacol Ther 2010;31(2):274-84
   PubMed Web of Science ®Google Scholar
• Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25(5):599-608
   PubMed Web of Science ®Google Scholar
• Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008;28(7):917-30
   PubMed Web of Science ®Google Scholar
• Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996;41(8):1636-42
   PubMed Web of Science ®Google Scholar
• Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999;44(2):226-30
   PubMed Web of Science ®Google Scholar
• Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000;46(4):522-6
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27(8):685-96
   PubMed Web of Science ®Google Scholar
• Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011;9(7):577-83
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009;7(5):502-8
   PubMed Web of Science ®Google Scholar
• Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000;129(8):1601-8
   PubMed Web of Science ®Google Scholar
• Gheuens J. Safety alerts for human medical products. Propulsid (cisapride) dear healthcare professional letter 2000
   Google Scholar
• Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Hear Circ Physiol 1997;273(5):H2534-8
   Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and FDA regulatory actions. Am J Gastroenterol 2001;96(6):1698-703
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20(2):99-112
   PubMed Web of Science ®Google Scholar
• Ganzini L. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153(12):1469
   PubMedGoogle Scholar
• Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 2013;58(1-2):150-6
   PubMed Web of Science ®Google Scholar
• Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22(1):42-9
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013;22(2):277-84
   PubMed Web of Science ®Google Scholar
• Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation–a double-blind study. Aliment Pharmacol Ther 2011;34(1):41-50
   PubMed Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled Phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106(10):1803-12
   PubMed Web of Science ®Google Scholar
• Cash BD, Chey WD. Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther 2005;22(11-12):1047-60
   PubMed Web of Science ®Google Scholar
• Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365(6):527-36
   PubMed Web of Science ®Google Scholar
• Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol 2010;3:49-56
   PubMedGoogle Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745-67
   PubMed Web of Science ®Google Scholar
• The European Medicines Agency. European public assessment report (EPAR) for Resolor (prucalopride). Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/001012/human_med_001030.jsp&mid=WC0b01ac058001d124 [Last accessed 16 October 2014]
   Google Scholar
• Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13(5):465-72
   PubMed Web of Science ®Google Scholar
• Mader R, Kocher T, Haier J, et al. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur J Gastroenterol Hepatol 2006;18(9):945-50
   PubMed Web of Science ®Google Scholar
• Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989;340(4):403-10
   PubMed Web of Science ®Google Scholar
• Markstein R, Matsumoto M, Kohler C, et al. Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1999;359(6):454-9
   PubMed Web of Science ®Google Scholar
• Prins NH, Akkermans LM, Lefebvre RA, et al. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131(5):927-32
   PubMed Web of Science ®Google Scholar
• Leclere PG, Prins NH, Schuurkes JA, et al. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005;17(3):366-75
   PubMed Web of Science ®Google Scholar
• Cellek S, John a K, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18(9):853-61
   PubMed Web of Science ®Google Scholar
• Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423(1):71-83
   PubMed Web of Science ®Google Scholar
• Van De Velde VJ, Ausma JJ, Vandeplassche LM. Kinetics and absolute oral bioavailability of prucalopride. Gastroenterology 2010;138(5 Suppl 1):S-230
   Google Scholar
• Van de Velde VA, Vandeplassche LM. Pharmacokinetics of prucalorpide (Resolor) in man. Gut 2008;57(Suppl):A282
   Google Scholar
• Winter HS, Van De Velde VJ, Ausma JJ, et al. A single-dose pharmacokinetic trial of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;136(Suppi 1):A510
   Google Scholar
• Van De Velde VJ, Ausma JJ, Vandeplassche LM. Food does not affect the oral bioavailability of prucalopride. Gastroenterology 2009;136:A536
   Web of Science ®Google Scholar
• Van De Velde VJ, Ausma JJ, Vandeplassche LM. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects. Gastroenterology 2010;138(5 Suppl):S-230
   Google Scholar
• Smith WB, Mannaert E, Verhaeghe T, et al. Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study. Drug Des Devel 2012;6:407-15
   PubMed Web of Science ®Google Scholar
• LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. Neurogastroenterol Motil 2004;16(3):355-64
   PubMed Web of Science ®Google Scholar
• Prins NH, Van Haselen JF, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999;127(6):1431-7
   PubMed Web of Science ®Google Scholar
• Qi H, Luo J, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J Gastroenterol 2003;9(9):2065-7
   PubMed Web of Science ®Google Scholar
• De Winter BY, Boeckxstaens GE, De Man JG, et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45(5):713-18
   PubMed Web of Science ®Google Scholar
• Prins NH, van Der Grijn A, Lefebvre RA, et al. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132(8):1941-7
   PubMed Web of Science ®Google Scholar
• Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002;135(1):135-42
   PubMed Web of Science ®Google Scholar
• Prins NH, Van Der Grijn A, Lefebvre RA, et al. 5-HT 4 receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132(8):1941-7
   PubMed Web of Science ®Google Scholar
• Briejer MR, Meulemans AL, Wellens A, et al. R093877 dose-dependently accelerates gastric emptying in conscious dogs. Gastroenterology 1997;112:A705
   Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44(5):682-6
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13(11):1493-7
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42(4):511-16
   PubMed Web of Science ®Google Scholar
• De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16(3):603-12
   PubMed Web of Science ®Google Scholar
• Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16(7):1347-56
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16(4):759-67
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Digestion 2003;67(1-2):82-9
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-54
   PubMed Web of Science ®Google Scholar
• Tack J, Outryve MV, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2008;58(3):357-65
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens RA. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29(3):315-28
   PubMed Web of Science ®Google Scholar
• Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014;26(1):21-7
   PubMed Web of Science ®Google Scholar
• Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32(9):1113-23
   PubMed Web of Science ®Google Scholar
• Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the asia-pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24(11):999-e541
   PubMed Web of Science ®Google Scholar
• Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol 2014;109(6):887-94
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39(3):239-53
   PubMed Web of Science ®Google Scholar
• Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment. Aliment. Pharmacol 2013;37(9):876-86
   PubMed Web of Science ®Google Scholar
• Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr 2013;57(2):197-203
   PubMed Web of Science ®Google Scholar
• Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no More Effective than Placebo for Children with Functional Constipation. Gastroenterology 2014;147(6):1285-95
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21(12):1256-e117
   PubMed Web of Science ®Google Scholar
• Van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006;101(10):2401-9
   PubMed Web of Science ®Google Scholar
• Gatandiuk S, Beyens G, Ausma J, et al. Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies. Gastroenterology 2008;134:A138
   Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012;35(1):48-55
   PubMed Web of Science ®Google Scholar
• Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37(4):431-6
   PubMed Web of Science ®Google Scholar
• D’Hooghe B, Guillaum D MR, et al. Treatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucalopride. Neurogastroenterol Motil 1999;11:A256
   Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil 2014;26(8):1079-86
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001;299(3):1007-12
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554(2-3):98-105
   PubMed Web of Science ®Google Scholar
• Boyce M, Kerstens R, Beyens G, et al. No Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials. Gastroenterology 2009;136:T1265
   Google Scholar
• NHS Regional Drug and Therapeutics Centre (Newcastle). Cost Comparison Charts. 2014
   Google Scholar